NCT06480123

Stem Cell Derived Exome for Treatment of Diabetic Foot

Skin Drug Prepared From Stem Cell Derived Exome for Treatment of Diabetic Foot: a Phase II Clinical Trial

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Second Affiliated Hospital of Guangzhou Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This trial is designed to investigate the safety and efficacy of patients with diabetic foot by using stem cell derived exome.

Detailed description

It is estimated that about 150 million people are suffering diabetes mellitus, of whom more than 15% will develop foot ulcers or gangrene at some times, so called diabetic foot. The diabetic foot is very difficult to cure by traditional approaches. This phase I clinical trial is designed to assess the safety and theraputical benefit of the stem cell derived exome.

Conditions

• Diabetic Foot
• Stem Cell

Interventions

Type	Name	Description
DRUG	Skin drug prepared with exome originated from stem cell	Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.

Timeline

• Start date: 2024-08-01
• Primary completion: 2028-12-30
• Completion: 2033-12-30
• First posted: 2024-06-28
• Last updated: 2024-06-28

Locations

1 site across 1 country: China